|Articles|August 15, 2002
Pending FDA approval: Cardinal Health to ready formulation for market
Irvine, CA-ISTA Pharmaceuticals and Cardinal Health will manufacture commercial quantities of Vitrase, a proprietary formulation of highly purified hyaluronidase, pending its FDA approval.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























